Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum
Go back to Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum| Myriad Genetics, Inc. (NASDAQ: MYGN) | Delayed: 4.63 +0.13 (2.89%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.50 | 52 Week High | $45.34 | |||
| Open | $4.41 | 52 Week Low | $15.92 | |||
| Day High | $4.71 | P/E | 1.99 | |||
| Day Low | $4.39 | EPS | $2.33 | |||
| Volume | 1,271,865 | |||||
